Biome Australia Ltd (AU:BIO)
ASX:BIO
BIO Stock Chart & Stats
AU$0.40
-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.40
-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$0.63
Previous CloseN/A
Volume242.26K
Average Volume (3M)278.69K
Market Cap
AU$72.64M
Enterprise ValueAU$71.71M
Total Cash (Recent Filing)AU$3.36M
Total Debt (Recent Filing)AU$2.43M
Price to Earnings (P/E)19.7
Beta1.39
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding226,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.12
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margin & Revenue GrowthSustained top-line growth with a 61% gross margin indicates durable product economics and pricing power in core formulations. High gross margin supports reinvestment in distribution and R&D, improving margins scalability as volumes grow over the medium term.
Broad Pharmacy/practitioner DistributionA multi-channel distribution model (pharmacies, practitioner clinics, retail/wholesale) reduces customer concentration and supports repeat purchases. Durable shelf presence and practitioner endorsement strengthen brand adoption and steady reorder frequency over months.
Improving Free Cash Flow & Manageable LeverageVery strong free cash flow growth signals improving cash generation capacity, while moderate leverage (D/E 0.66) and positive ROE provide financial flexibility. Together these support funding of working capital and targeted growth without excessive dilution or refinancing risk.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow shows earnings aren’t converting to cash, constraining the firm's ability to fund inventories, marketing or R&D internally. Over months this can force reliance on external financing, increasing execution and refinancing risk.
Thin Net ProfitabilityVery slim net margins leave little buffer for cost shocks or investment. Despite healthy gross margins, low net profitability suggests high operating costs or scale limits, limiting retained earnings to fund growth and making earnings vulnerable to margin pressure.
Small Scale & Australia ConcentrationLimited geographic diversification and small organizational scale constrain market reach and resilience. Concentration in Australia's channels increases exposure to local regulatory or retail shifts and can slow expansion unless the company executes international or category expansion.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.30 and its highest was AU$0.63 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$72.64M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Jul 28, 2026 which is in 121 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Feb 22, 2026. The company reported AU$0.005 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.001.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 226,998,030 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.005 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (150.00% Upside)
AU$1.00 (150.00% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$15.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
17.85%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Biome Australia Ltd
Biome Australia Limited develops, commercializes, and markets various live biotherapeutics and complimentary medicines in Australia and internationally. It provides live biotherapeutic products under the Activated Probiotics brand; organic nutraceutical products under the Activated Nutrients brand; and sports performance and recovery products under the Activated X Performance brand. The company markets its products through community pharmacies and independent health practitioners. Biome Australia Limited was incorporated in 2018 and is based in Cremorne, Australia.
BIO Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(150.00% Upside)
Technical Analysis
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---